Revenue earned during the period relating to collaboration arrangement.

No definition available.

Name:	qure_CollaborationRevenue
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of costs that counterparty has agreed to pay, and for which the reporting entity recognizes as collaboration revenue.

+ References

No definition available.

+ Details

Name:	qure_CollaborativeArrangementCostSharingPercentage
Namespace Prefix:	qure_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduction in License Revenue Due to Prior Amortization

+ References

No definition available.

+ Details

Name:	qure_ReductionInLicenseRevenueDueToPriorAmortization
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The up-front payment received as of the effective date of the collaboration agreement,

+ References

No definition available.

+ Details

Name:	qure_UpfrontPaymentReceived
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously reported as deferred or unearned revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=qure_CollaborativeArrangementLicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=qure_ChiesiPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=qure_GlyberaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration arrangements and concentration of credit risk - Chiesi collaboration (Details) $ in Thousands, € in Millions			1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2013 EUR (€)	Sep. 30, 2013 USD ($)	Jul. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016
Collaboration arrangements
License revenues				$ 246	$ 8	$ 736
Percentage of costs to be paid by counterparty							50.00%
Collaboration Revenue				$ 1,850	4,638	$ 4,835
License revenue \| Chiesi Pharmaceutical
Collaboration arrangements
Up-front payment received	€ 17.0	$ 22,100
Fully released outstanding deferred revenue recorded in other income			$ 13,800
Glybera \| License revenue \| Chiesi Pharmaceutical
Collaboration arrangements
Reduction to license revenue that was previously amortized and repaid by the Company in accordance with the Termination Agreement					$ 500